Global Prostate Cancer Nuclear Medicine Diagnostics Market
Global Prostate Cancer Nuclear Medicine Diagnostics Market

Prostate Cancer Nuclear Medicine Diagnostics Comprehensive Study by Type (Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET)), Application (Hospitals, Clinics, Others), (), PET product (F-18, C-11, Ga 68 PSMA, Other) Players and Region - Global Market Outlook to 2027

Prostate Cancer Nuclear Medicine Diagnostics Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 212 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Prostate Cancer Nuclear Medicine Diagnostics?
Prostate cancer is cancer that develops in the tissues of the prostate. Prostate cancer is most commonly found in elderly men. Fats promote the synthesis of testosterone and other hormones, and testosterone has been shown to hasten prostate cancer growth. High testosterone levels have been linked to the reactivation of latent prostate cancer cells. Nuclear medicine and radiology both employ radiation. Radioactive materials are known as radioisotopes, or radiopharmaceuticals, are administered into the body in nuclear medicine. X-rays enter the body from the outside in radiology. A wide range of illnesses can be diagnosed using nuclear medicine. A radiopharmaceutical will be given to the patient via inhalation, swallowing, or injection. This substance is radioactive. The patient will often lie down on a table after taking the substance while a camera captures pictures. The camera will focus on the area where the radioactive material is concentrated, allowing the doctor to see what kind of issue exists and where it is located.

The market study is broken down by Type (Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)), by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.

The nuclear medicine diagnostic market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing on the technologies and new machines implementations. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge investment in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Prostate Cancer Nuclear Medicine Diagnostics market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Blue Earth Diagnostics (United Kingdom), Lantheus Medical Imagining, Inc. (United States), Theragnostics Ltd (United Kingdom), Curium Pharma (Finland), Jubilant Pharma Limited (United States), NCM-USA LLC (United States), Telix Pharmaceuticals Ltd. (Australia), Cancer Genetics, Inc. (United States), Sun Nuclear Corporation (United States) and American Pride (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are PETNET Solutions Inc. (United States), Cardinal Health (United States), ImaginAb (United States) and Novartis AG (Switzerland).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Prostate Cancer Nuclear Medicine Diagnostics market by Type, Application and Region.

On the basis of geography, the market of Prostate Cancer Nuclear Medicine Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by , the sub-segment i.e. will boost the Prostate Cancer Nuclear Medicine Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by PET product, the sub-segment i.e. F-18 will boost the Prostate Cancer Nuclear Medicine Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In May 2021- GE Healthcare launched Xeleris V, a new virtual processing and review system, to give nuclear medicine professionals more freedom and time with patients. Xeleris V eliminates the need for a separate nuclear medicine workstation, allowing doctors to view data securely from several locations. This increase in access, when combined with new AI-enabled applications and GE Healthcare's vast installed base of nuclear medicine cameras, can help physicians discover, diagnose, and treat patients more accurately.


Market Trend
  • Rising Demand for Early and Precise Diagnosis of the Disease
  • Increasing research activities for the development of innovative imaging

Market Drivers
  • Rising Prevalence of Prostate Cancer
  • The presence of reimbursement policies is expected to further fuel the growth of nuclear medicine diagnostics

Opportunities
  • Adoption of PET as a diagnostic tool is significantly increasing
  • Increasing demand for PET diagnostic procedures due to higher accuracy

Restraints
  • The high cost of the test hampers the market

Challenges
  • Earlier Detection of Prostate Cancer in the PSA Era


Key Target Audience
Nuclear medicine Diagnostics Companies, Healthcare and Pharmaceutical Companies, Consulting and Advisory Firms, Government and Policy Makers and Regulatory Authorities

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Blue Earth Diagnostics (United Kingdom), Lantheus Medical Imagining, Inc. (United States), Theragnostics Ltd (United Kingdom), Curium Pharma (Finland), Jubilant Pharma Limited (United States), NCM-USA LLC (United States), Telix Pharmaceuticals Ltd. (Australia), Cancer Genetics, Inc. (United States), Sun Nuclear Corporation (United States) and American Pride (United States) etc.

2. Can we have customized study for Prostate Cancer Nuclear Medicine Diagnostics Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Prostate Cancer Nuclear Medicine Diagnostics Market by 2027?
Analysts at AMA estimates Prostate Cancer Nuclear Medicine Diagnostics Market to reach USD Million by 2027.
Report Objectives / Segmentation Covered
By Type
  • Single-Photon Emission Computed Tomography (SPECT)
  • Positron Emission Tomography (PET)
By Application
  • Hospitals
  • Clinics
  • Others
By PET product
  • F-18
  • C-11
  • Ga 68 PSMA
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Prostate Cancer
      • 3.2.2. The presence of reimbursement policies is expected to further fuel the growth of nuclear medicine diagnostics
    • 3.3. Market Challenges
      • 3.3.1. Earlier Detection of Prostate Cancer in the PSA Era
    • 3.4. Market Trends
      • 3.4.1. Rising Demand for Early and Precise Diagnosis of the Disease
      • 3.4.2. Increasing research activities for the development of innovative imaging
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Prostate Cancer Nuclear Medicine Diagnostics, by Type, Application, , PET product and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Prostate Cancer Nuclear Medicine Diagnostics (Value)
      • 5.2.1. Global Prostate Cancer Nuclear Medicine Diagnostics by: Type (Value)
        • 5.2.1.1. Single-Photon Emission Computed Tomography (SPECT)
        • 5.2.1.2. Positron Emission Tomography (PET)
      • 5.2.2. Global Prostate Cancer Nuclear Medicine Diagnostics by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Prostate Cancer Nuclear Medicine Diagnostics by: PET product (Value)
        • 5.2.3.1. F-18
        • 5.2.3.2. C-11
        • 5.2.3.3. Ga 68 PSMA
        • 5.2.3.4. Other
      • 5.2.4. Global Prostate Cancer Nuclear Medicine Diagnostics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Prostate Cancer Nuclear Medicine Diagnostics (Price)
      • 5.3.1. Global Prostate Cancer Nuclear Medicine Diagnostics by: Type (Price)
  • 6. Prostate Cancer Nuclear Medicine Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Blue Earth Diagnostics (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lantheus Medical Imagining, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Theragnostics Ltd (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Curium Pharma (Finland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Jubilant Pharma Limited (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. NCM-USA LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Telix Pharmaceuticals Ltd. (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cancer Genetics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sun Nuclear Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. American Pride (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Prostate Cancer Nuclear Medicine Diagnostics Sale, by Type, Application, , PET product and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Prostate Cancer Nuclear Medicine Diagnostics (Value)
      • 7.2.1. Global Prostate Cancer Nuclear Medicine Diagnostics by: Type (Value)
        • 7.2.1.1. Single-Photon Emission Computed Tomography (SPECT)
        • 7.2.1.2. Positron Emission Tomography (PET)
      • 7.2.2. Global Prostate Cancer Nuclear Medicine Diagnostics by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Prostate Cancer Nuclear Medicine Diagnostics by: PET product (Value)
        • 7.2.3.1. F-18
        • 7.2.3.2. C-11
        • 7.2.3.3. Ga 68 PSMA
        • 7.2.3.4. Other
      • 7.2.4. Global Prostate Cancer Nuclear Medicine Diagnostics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Prostate Cancer Nuclear Medicine Diagnostics (Price)
      • 7.3.1. Global Prostate Cancer Nuclear Medicine Diagnostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Prostate Cancer Nuclear Medicine Diagnostics: by Type(USD Million)
  • Table 2. Prostate Cancer Nuclear Medicine Diagnostics Single-Photon Emission Computed Tomography (SPECT) , by Region USD Million (2016-2021)
  • Table 3. Prostate Cancer Nuclear Medicine Diagnostics Positron Emission Tomography (PET) , by Region USD Million (2016-2021)
  • Table 4. Prostate Cancer Nuclear Medicine Diagnostics: by Application(USD Million)
  • Table 5. Prostate Cancer Nuclear Medicine Diagnostics Hospitals , by Region USD Million (2016-2021)
  • Table 6. Prostate Cancer Nuclear Medicine Diagnostics Clinics , by Region USD Million (2016-2021)
  • Table 7. Prostate Cancer Nuclear Medicine Diagnostics Others , by Region USD Million (2016-2021)
  • Table 8. Prostate Cancer Nuclear Medicine Diagnostics: by PET product(USD Million)
  • Table 9. Prostate Cancer Nuclear Medicine Diagnostics F-18 , by Region USD Million (2016-2021)
  • Table 10. Prostate Cancer Nuclear Medicine Diagnostics C-11 , by Region USD Million (2016-2021)
  • Table 11. Prostate Cancer Nuclear Medicine Diagnostics Ga 68 PSMA , by Region USD Million (2016-2021)
  • Table 12. Prostate Cancer Nuclear Medicine Diagnostics Other , by Region USD Million (2016-2021)
  • Table 13. South America Prostate Cancer Nuclear Medicine Diagnostics, by Country USD Million (2016-2021)
  • Table 14. South America Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 15. South America Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 16. South America Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 17. Brazil Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 18. Brazil Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 19. Brazil Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 20. Argentina Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 21. Argentina Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 22. Argentina Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 23. Rest of South America Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 24. Rest of South America Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 25. Rest of South America Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 26. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics, by Country USD Million (2016-2021)
  • Table 27. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 28. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 29. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 30. China Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 31. China Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 32. China Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 33. Japan Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 34. Japan Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 35. Japan Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 36. India Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 37. India Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 38. India Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 39. South Korea Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 40. South Korea Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 41. South Korea Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 42. Australia Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 43. Australia Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 44. Australia Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 45. Rest of Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 48. Europe Prostate Cancer Nuclear Medicine Diagnostics, by Country USD Million (2016-2021)
  • Table 49. Europe Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 50. Europe Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 51. Europe Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 52. Germany Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 53. Germany Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 54. Germany Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 55. France Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 56. France Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 57. France Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 58. Italy Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 59. Italy Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 60. Italy Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 61. United Kingdom Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 62. United Kingdom Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 63. United Kingdom Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 64. Netherlands Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 65. Netherlands Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 66. Netherlands Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 67. Rest of Europe Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 68. Rest of Europe Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 69. Rest of Europe Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 70. MEA Prostate Cancer Nuclear Medicine Diagnostics, by Country USD Million (2016-2021)
  • Table 71. MEA Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 72. MEA Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 73. MEA Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 74. Middle East Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 75. Middle East Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 76. Middle East Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 77. Africa Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 78. Africa Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 79. Africa Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 80. North America Prostate Cancer Nuclear Medicine Diagnostics, by Country USD Million (2016-2021)
  • Table 81. North America Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 82. North America Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 83. North America Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 84. United States Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 85. United States Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 86. United States Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 87. Canada Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 88. Canada Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 89. Canada Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 90. Mexico Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2016-2021)
  • Table 91. Mexico Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2016-2021)
  • Table 92. Mexico Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2016-2021)
  • Table 93. Prostate Cancer Nuclear Medicine Diagnostics: by Type(USD/Units)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Prostate Cancer Nuclear Medicine Diagnostics: by Type(USD Million)
  • Table 105. Prostate Cancer Nuclear Medicine Diagnostics Single-Photon Emission Computed Tomography (SPECT) , by Region USD Million (2022-2027)
  • Table 106. Prostate Cancer Nuclear Medicine Diagnostics Positron Emission Tomography (PET) , by Region USD Million (2022-2027)
  • Table 107. Prostate Cancer Nuclear Medicine Diagnostics: by Application(USD Million)
  • Table 108. Prostate Cancer Nuclear Medicine Diagnostics Hospitals , by Region USD Million (2022-2027)
  • Table 109. Prostate Cancer Nuclear Medicine Diagnostics Clinics , by Region USD Million (2022-2027)
  • Table 110. Prostate Cancer Nuclear Medicine Diagnostics Others , by Region USD Million (2022-2027)
  • Table 111. Prostate Cancer Nuclear Medicine Diagnostics: by PET product(USD Million)
  • Table 112. Prostate Cancer Nuclear Medicine Diagnostics F-18 , by Region USD Million (2022-2027)
  • Table 113. Prostate Cancer Nuclear Medicine Diagnostics C-11 , by Region USD Million (2022-2027)
  • Table 114. Prostate Cancer Nuclear Medicine Diagnostics Ga 68 PSMA , by Region USD Million (2022-2027)
  • Table 115. Prostate Cancer Nuclear Medicine Diagnostics Other , by Region USD Million (2022-2027)
  • Table 116. South America Prostate Cancer Nuclear Medicine Diagnostics, by Country USD Million (2022-2027)
  • Table 117. South America Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 118. South America Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 119. South America Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 120. Brazil Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 121. Brazil Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 122. Brazil Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 123. Argentina Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 124. Argentina Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 125. Argentina Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 126. Rest of South America Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 127. Rest of South America Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 128. Rest of South America Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 129. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics, by Country USD Million (2022-2027)
  • Table 130. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 131. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 132. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 133. China Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 134. China Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 135. China Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 136. Japan Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 137. Japan Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 138. Japan Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 139. India Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 140. India Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 141. India Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 142. South Korea Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 143. South Korea Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 144. South Korea Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 145. Australia Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 146. Australia Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 147. Australia Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 148. Rest of Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 149. Rest of Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 150. Rest of Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 151. Europe Prostate Cancer Nuclear Medicine Diagnostics, by Country USD Million (2022-2027)
  • Table 152. Europe Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 153. Europe Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 154. Europe Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 155. Germany Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 156. Germany Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 157. Germany Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 158. France Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 159. France Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 160. France Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 161. Italy Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 162. Italy Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 163. Italy Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 164. United Kingdom Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 165. United Kingdom Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 166. United Kingdom Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 167. Netherlands Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 168. Netherlands Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 169. Netherlands Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 170. Rest of Europe Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 171. Rest of Europe Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 172. Rest of Europe Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 173. MEA Prostate Cancer Nuclear Medicine Diagnostics, by Country USD Million (2022-2027)
  • Table 174. MEA Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 175. MEA Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 176. MEA Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 177. Middle East Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 178. Middle East Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 179. Middle East Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 180. Africa Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 181. Africa Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 182. Africa Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 183. North America Prostate Cancer Nuclear Medicine Diagnostics, by Country USD Million (2022-2027)
  • Table 184. North America Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 185. North America Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 186. North America Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 187. United States Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 188. United States Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 189. United States Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 190. Canada Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 191. Canada Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 192. Canada Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 193. Mexico Prostate Cancer Nuclear Medicine Diagnostics, by Type USD Million (2022-2027)
  • Table 194. Mexico Prostate Cancer Nuclear Medicine Diagnostics, by Application USD Million (2022-2027)
  • Table 195. Mexico Prostate Cancer Nuclear Medicine Diagnostics, by PET product USD Million (2022-2027)
  • Table 196. Prostate Cancer Nuclear Medicine Diagnostics: by Type(USD/Units)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Prostate Cancer Nuclear Medicine Diagnostics: by Type USD Million (2016-2021)
  • Figure 5. Global Prostate Cancer Nuclear Medicine Diagnostics: by Application USD Million (2016-2021)
  • Figure 6. Global Prostate Cancer Nuclear Medicine Diagnostics: by PET product USD Million (2016-2021)
  • Figure 7. South America Prostate Cancer Nuclear Medicine Diagnostics Share (%), by Country
  • Figure 8. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Share (%), by Country
  • Figure 9. Europe Prostate Cancer Nuclear Medicine Diagnostics Share (%), by Country
  • Figure 10. MEA Prostate Cancer Nuclear Medicine Diagnostics Share (%), by Country
  • Figure 11. North America Prostate Cancer Nuclear Medicine Diagnostics Share (%), by Country
  • Figure 12. Global Prostate Cancer Nuclear Medicine Diagnostics: by Type USD/Units (2016-2021)
  • Figure 13. Global Prostate Cancer Nuclear Medicine Diagnostics share by Players 2021 (%)
  • Figure 14. Global Prostate Cancer Nuclear Medicine Diagnostics share by Players (Top 3) 2021(%)
  • Figure 15. Global Prostate Cancer Nuclear Medicine Diagnostics share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Blue Earth Diagnostics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Blue Earth Diagnostics (United Kingdom) Revenue: by Geography 2021
  • Figure 19. Lantheus Medical Imagining, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Lantheus Medical Imagining, Inc. (United States) Revenue: by Geography 2021
  • Figure 21. Theragnostics Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Theragnostics Ltd (United Kingdom) Revenue: by Geography 2021
  • Figure 23. Curium Pharma (Finland) Revenue, Net Income and Gross profit
  • Figure 24. Curium Pharma (Finland) Revenue: by Geography 2021
  • Figure 25. Jubilant Pharma Limited (United States) Revenue, Net Income and Gross profit
  • Figure 26. Jubilant Pharma Limited (United States) Revenue: by Geography 2021
  • Figure 27. NCM-USA LLC (United States) Revenue, Net Income and Gross profit
  • Figure 28. NCM-USA LLC (United States) Revenue: by Geography 2021
  • Figure 29. Telix Pharmaceuticals Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 30. Telix Pharmaceuticals Ltd. (Australia) Revenue: by Geography 2021
  • Figure 31. Cancer Genetics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Cancer Genetics, Inc. (United States) Revenue: by Geography 2021
  • Figure 33. Sun Nuclear Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 34. Sun Nuclear Corporation (United States) Revenue: by Geography 2021
  • Figure 35. American Pride (United States) Revenue, Net Income and Gross profit
  • Figure 36. American Pride (United States) Revenue: by Geography 2021
  • Figure 37. Global Prostate Cancer Nuclear Medicine Diagnostics: by Type USD Million (2022-2027)
  • Figure 38. Global Prostate Cancer Nuclear Medicine Diagnostics: by Application USD Million (2022-2027)
  • Figure 39. Global Prostate Cancer Nuclear Medicine Diagnostics: by PET product USD Million (2022-2027)
  • Figure 40. South America Prostate Cancer Nuclear Medicine Diagnostics Share (%), by Country
  • Figure 41. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Share (%), by Country
  • Figure 42. Europe Prostate Cancer Nuclear Medicine Diagnostics Share (%), by Country
  • Figure 43. MEA Prostate Cancer Nuclear Medicine Diagnostics Share (%), by Country
  • Figure 44. North America Prostate Cancer Nuclear Medicine Diagnostics Share (%), by Country
  • Figure 45. Global Prostate Cancer Nuclear Medicine Diagnostics: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Blue Earth Diagnostics (United Kingdom)
  • Lantheus Medical Imagining, Inc. (United States)
  • Theragnostics Ltd (United Kingdom)
  • Curium Pharma (Finland)
  • Jubilant Pharma Limited (United States)
  • NCM-USA LLC (United States)
  • Telix Pharmaceuticals Ltd. (Australia)
  • Cancer Genetics, Inc. (United States)
  • Sun Nuclear Corporation (United States)
  • American Pride (United States)
Additional players considered in the study are as follows:
PETNET Solutions Inc. (United States) , Cardinal Health (United States) , ImaginAb (United States) , Novartis AG (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation